Mark Awad

Chief, Thoracic Oncology Service

Memorial Sloan Kettering Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Mark Awad serves as the Chief of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in the United States. His research focuses on advanced non-small-cell lung cancer, with recent publications addressing biomarker-directed therapies, genomic and immunophenotypic resistance patterns, and the role of machine learning in assessing treatment outcomes. His contributions to the field include studies on immunotherapy combinations, liquid biopsy profiling, and the effectiveness of various therapeutic strategies in lung cancer treatment.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (3)

sylvia hartl

Head of Institute

AUSTRIA

View details

Benjamin Besse

Université Paris-Saclay

FRANCE

View details

Maria Libera Ascierto

Professor

University of Glasgow

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mark Awad

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial

Correction to: Liquid biopsy epigenomic profiling for cancer subtyping (Nature Medicine, (2023), 29, 11, (2737-2741), 10.1038/s41591-023-02605-z)

Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial

ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer

Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival

Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images with Outcomes of Immunotherapy in Patients with NSCLC

Atezolizumab Plus Bevacizumab in TMB-High Non-Small Cell Lung Cancers - The Hunt for Predictive Biomarkers to Optimize Treatment Selection

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC

Collaborators (3)

sylvia hartl

Benjamin Besse

Maria Libera Ascierto

Make your next move.